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Self-monitoring of blood pressure by patients at home
(home blood pressure monitoring (HBPM)) is being
increasingly used in many countries and is well accepted
by hypertensive patients. Current hypertension guidelines
have endorsed the use of HBPM in clinical practice as
a useful adjunct to conventional office measurements.
Recently, a detailed consensus document on HBPM was
published by the European Society of Hypertension
Working Group on Blood Pressure Monitoring. However,
in daily practice, briefer documents summarizing the
essential recommendations are needed. It is also accepted
that the successful implementation of clinical guidelines in
routine patient care is dependent on their acceptance by
involvement of practising physicians. The present docu-
ment, which provides concise and updated guidelines on
the use of HBPM for practising physicians, was therefore
prepared by including the comments and feedback of
general practitioners.
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Self-monitoring of blood pressure by patients at
home (home blood pressure monitoring (HBPM)) is
being increasingly used in many countries and is
well accepted by hypertensive patients.1–7 Current
hypertension guidelines have endorsed the use of
HBPM in clinical practice as a useful adjunct to
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the conventional office measurements.1–7 In 2008 a
detailed consensus document on HBPM was pub-
lished by the European Society of Hypertension
Working Group on Blood Pressure Monitoring.1
However, in daily practice, briefer documents sum-
marizing the essential recommendations are needed.
It is also accepted that the successful implementa-
tion of clinical guidelines in routine patient care
is dependent on their acceptance by involvement of
practising physicians. Therefore, this practice guide-
lines document on HBPM use was prepared by
including the comments and feedbacks of two groups
of general practitioners (see Acknowledgements).
HBPM: advantages—prerequisites
HBPM has several major advantages over conven-
tional office blood pressure (BP) measurement: (1) it
provides multiple measurements of BP in different
days, weeks or months; (2) these measurements are
made in the usual environment of each individual,
away from the physician’s office, a setting known to
cause a BP increase in many subjects (white-coat
effect); (3) home BP is more closely related to
hypertension-induced target organ damage and
predicts the risk of cardiovascular events better
than conventional office measurements (Boxes 1
and 2). HBPM can detect the white-coat and masked
hypertension phenomena, and it shares most of the
above features with 24-h ambulatory BP monitoring
(ABPM), another important technique for out-of-
office BP monitoring (Box 1).1–4 Compared with
ABPM, HBPM provides measurements over a much
longer period, is cheaper, more widely available,
more convenient for patients particularly for re-
peated measurements, and has been shown to
improve patients’ compliance with treatment and
hypertension control rates.1–4,8 However, unlike
ABPM it does not allow the assessment of BP during
sleep or at work, or the quantification of short-term
BP variability, although it may be possible to assess
day by day BP variability,9,10 thus offering a means to
quantify long-term BP variations which, as recently
suggested, may have prognostic significance.11
Moreover, HBPM can be used as an educational tool
in hypertensive patients for improving the under-
standing of their disease and its follow-up. Thus, it
seems to be an appropriate method for the long-term
follow-up of treated hypertension and is often used
in conjunction with ABPM as a complementary
method of BP assessment (Box 1).
There are important prerequisites for the optimal
application of HBPM in clinical practice (Box 2).
HBPM should be performed by patients who have
been trained under medical supervision, and trained
nurses and/or pharmacists can have an important
part in the implementation of HBPM in daily practice
and in the diffusion of correct recommendations.
Box 1 Summary of advantages and limitations of HBPM (modified with permission from Parati et al.1)
Advantages Limitations
A number of measurements of blood pressure and heart rate
during the day and also over several days, weeks or months are
possible.
Need of patient training (simple for automated devices).
Assessment of treatment effects at different times of the day and
over extended periods.
Possible use of inaccurate devices.
No alarm (white-coat) reaction to blood pressure measurement. Measurement errors.
Diagnosis of white-coat and masked hypertension. Questionable reliability of blood pressure values reported by
patients.
Good reproducibility. Induction of anxiety, resulting in excessive monitoring.
Good prognostic value. Risk of treatment changes made by patients on the basis of
casual home measurements without doctor’s guidance.
Relatively low cost. Normality thresholds and therapeutic targets still debated,
mainly in patients at high cardiovascular risk.
Patient-acceptance. Lack of night-time recordings.
Education tool—involvement of patients in hypertension
management.
Absence of reimbursement by insurance company or social
security in most countries.
Possibility of digital storage, printout, PC download or
teletransmission of blood pressure values (some devices).
Improvement of patients’ compliance to drug treatment.
Improvement of hypertension control rates.
Abbreviation: HBPM, home blood pressure monitoring.
Box 2 Key issues related to the methodology of HBPM
Medical supervision and patient training (see online
Supplementary Material).
Appropriate choice of validated HBPM devices. Specific
validation required in special populations (elderly, children,
normal pregnancy, pre-eclampsia, end-stage renal disease and
arrhythmias).
Adequate blood pressure measurements schedule and data
reporting by patient.
Ability of physician to interpret the results correctly
(averaging of values and normal thresholds).
Abbreviation: HBPM, home blood pressure monitoring.
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Training should include information regarding hyper-
tension, BP variability, conditions and procedure
for self-monitoring, advice on equipment choice
(based on validation, technical features, price and
individual experience) and its proper use, and inter-
pretation of results (see Supplementary material).
The HBPM technique, when applied using electronic
devices, is not particularly complex and can be
explained to the patient during a single training
session (possibly with subsequent periodic verifica-
tion of correct monitoring performance during office
visits). However, in some patients (in particular
the elderly with motor or cognitive impairment
and in young children), the support of a trained
nurse or family member may be needed. Telephonic
assistance for patients having doubts or problems
with correct HBPM performance may prove to
be useful. A standardized BP logbook structured
according to the required monitoring schedule is
useful for ensuring the accuracy of data reporting
and for improving adherence to measurements
schedule (see Supplementary material). Manufac-
turers can facilitate HBPM by providing devices
with a range of cuffs for varying arm sizes and
capable of automatically calculating average BP. The
provision of telemonitoring facilities may be of
further advantage.12
Devices and cuffs
The conventional mercury sphygmomanometer,
regarded as the gold standard for BP measurement,
is being progressively banned in several countries
for environmental reasons (Box 3). Aneroid devices
are more prone to inaccuracy than mercury de-
vices.1,2,4 Moreover, patients only rarely master the
auscultatory technique required for using these
devices. Therefore, except for special cases (for
example, patients with arrhythmias trained in
auscultatory BP measurement) the use of ausculta-
tory devices (mercury, aneroid or other) is not
recommended for HBPM.
Semi-automated (manual cuff inflation) or auto-
mated electronic devices that measure BP at the
level of the upper arm are preferred for HBPM.1–5
These devices require less training, avoid observer
bias, and, if equipped with an automated memory,
have the potential to prevent patients from mis-
reporting their BP measurements.13,14
Finger devices are less accurate and more suscep-
tible to flaws in measurement technique and are not
recommended. Wrist devices are not recommended,
because they are more subject to inaccuracies
(incorrect position in relation to the heart, measure-
ment of BP in two arteries—radial and ulnar,
peripheral pulse wave distortion, and so on), and
are best avoided, unless brachial measurements are
difficult or impossible to obtain (for example, in
subjects with very large arm circumference or
extreme obesity).1,2,4
Among the large number of HBPM devices
available on the market only those that have been
validated for accuracy in independent studies
performed according to internationally recognized
protocols should be used.15,16 Up to date lists of
validated devices are available at the dedicated
websites (for example, www.dableducational.org,
www.bhsoc.org and www.pressionearteriosa.net).
It should not be assumed that a device that has been
validated in the general population will be accurate
in special circumstances, such as obesity, patients
with arrhythmias, older age, children or pregnancy
in which devices should be specifically validated.
The selection of the appropriate size of the cuff to
fit the arm of each individual is essential for an
accurate BP measurement (the inflatable bladder of
the cuff should cover 80–100% of the individual’s
arm circumference).1,2,4 The use of a small cuff for
the size of the arm can result in overestimation of
BP, whereas a too large one in its underestimation.
Although standard cuffs are appropriate for most
patients, in those with small (o24 cm) or large
(432 cm) arm circumference only the devices
equipped with appropriate sized cuffs should be
used.
Conditions of measurement
Conditions under which HBPM is performed can
greatly affect the measured BP levels (Box 4). The
cuff should be wrapped around the arm with its
inflatable bladder centred on the arm anterior
surface (most cuffs have an indication of proper
placement) with the lower edge of the cuff approxi-
mately 2–3 cm above the bend of the elbow. The
bladder should be positioned at the heart level
(particular attention must be paid to this recom-
mendation if, for any reason, a wrist device is used).
The measurement should be performed in a quiet
room and the patient should remain seated comfor-
tably, immobile with the arm resting on a table or
other support and should not talk. The results
should be reported in a logbook immediately after
each measurement. Alternatively, memory equipped
Box 3 Devices for HBPM
Only validated semi-automated or automated oscillometric
(electronic) arm cuff devices are recommended.
Devices with memory are preferred.
Auscultatory (aneroid or mercury) devices are not
recommended except under specific circumstances (for
example, arrhythmia, requiring repeated auscultatory
measurements).
Finger cuff devices not recommended.
Wrist cuff devices are not recommended at present, yet possible
applications are still under investigation, as in the case of
patients in whom brachial BP measurements are impossible
or very difficult (for example, extreme obesity).
Appropriately sized (small, standard or large) cuffs should be
used according to arm circumference.
Abbreviation: HBPM, home blood pressure monitoring.
Home blood pressure monitoring
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devices, which are recommended, can store the
readings with time and date for each measurement.
Sometimes devices are used to measure BP in other
family members and it is important to ensure that
these are not included with a patient measurement.
In rare cases of significant (410mmHg) and con-
sistent BP difference between arms, the physician
should advise the patient to use the arm with higher
BP values also for HBPM.
Monitoring schedule
For the initial evaluation of hypertension and the
assessment of the effects of antihypertensive treat-
ment (including changes in drug or dose) HBPM
should be performed daily during at least 3 and
preferably 7 days before the doctor’s visit (Box 5).
Duplicate measurements should be obtained in the
morning (before drug intake if treated) and in the
evening.17 Measurements of the first monitoring day
are usually higher and unstable and are excluded.
Treated hypertensive patients may also perform less
frequent, regular home BP measurements as a long-
term follow-up (for example, once or twice per
week), with the additional aim to reinforce their
compliance with treatment. However, this issue is
still matter of debate and isolated readings should
never be used for diagnostic purposes.1–4 Overuse of
the method and self-modification of treatment on
the basis of HBPM should be avoided.
Interpretation of HBPM
The average of a series of measurements taken as
described above should be used for the clinical
decisions based on HBPM readings (Box 6). Casual,
isolated home measurements can be very misleading
and should not by themselves constitute the basis
for clinical decisions. The users should be informed
that BP may vary between measurements and be
instructed not to be alarmed by high or low BP
measured on a single occasion, unless an important
elevation or reduction persists or is associated with
symptoms of clinical relevance (for example, dys-
pnoea, chest pain). Average systolic home BP
X135mmHg and/or diastolic X85mmHg indicates
elevated BP. The levels of ‘normal’ and ‘optimal’
home BP are still under investigation, provisionally
suggested values being o130/80mmHg for normal
home BP.1–4,18 Therapeutic decisions based on home
monitored BP should always take into consideration
overall cardiovascular risk profile and comorbidi-
ties. In high-risk subjects (for example, those with
diabetes or chronic kidney disease) lower home BP
values should probably be achieved but the targets
have not yet been defined.
Discrepancies between home and office BP
In the majority of patients, HBPM will lead to the
same clinical conclusion regarding the diagnosis of
hypertension as the conventional office measure-
ments (normotension or controlled hypertension if
both are normal; uncontrolled hypertension if both
are elevated). However, cases of disagreement in
diagnosis between office and home (or ambulatory)
BP measurements are not uncommon in both
untreated and treated subjects. Elevated BP in the
office with low home (or ambulatory) BP is known
as ‘white-coat’ (or ‘isolated office’) hypertension.
Conversely, normal BP in the office with elevated
home (or ambulatory) BP has been termed masked
hypertension.1–4,19–21 These diagnostic conclusions
should be reinforced by performing further investi-
gations including repeated office BP measurements
and either a repeated session of HBPM or a 24-h
ABPM.4,19,22
Subjects with white-coat hypertension are at a
marginally increased cardiovascular risk and also
at an increased risk to develop sustained hyper-
tension.4,22 Therefore, they should be regularly
followed using office and home BP measurements.
On the other hand masked hypertension is associated
with increased risk of cardiovascular events, similar
Box 4 Conditions of measurement
At least 5-min rest, 30min without smoking, meal, caffeine
intake or physical exercise.
Seated position in a quiet room, back supported, arm supported
(for example, resting on the table).
Subject immobile, legs uncrossed, not talking and relaxed.
Correct cuff bladder placement at heart level.
Results immediately reported in a specific logbook or stored
in device memory.
Box 5 Monitoring schedule
Seven-day home measurements (minimum 3 days).
At initial assessment, when assessing treatment effects, and in
the long-term follow-up before each clinic/office visit.
Morning (before drug intake if treated) and evening (before
eating) readings per day.
Two measurements per occasion (1–2min apart).
Long-term follow-up: less frequent measurements (for example,
once or twice per week) could be regularly performed aimed
at reinforcing compliance, although isolated readings should
never be used for diagnostic purposes.
Overuse of the method and self-modification of treatment
should be avoided.
Box 6 Interpretation of home BP readings
Average BP from several monitoring days should be considered
(for schedule see Box 5).
BP values measured on the first monitoring day should be
discarded.
Mean home systolic BP X135mmHg and/or diastolic
BPX85mmHg should be considered as elevated.
Systolic and diastolic home BP o130 and o80mmHg,
respectively, should be considered normal in most subjects.
In high-risk subjects home BP targets should probably be lower.
Abbreviation: blood pressure.
Home blood pressure monitoring
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to that of uncontrolled hypertension.23 Given this
between-method discrepancy, treatment decisions
in white-coat and masked hypertension should
probably be made on the basis of both office and
out-of-office BP measurements (the latter through
ABPM or HBPM, provided that they are reliable
and have been repeatedly performed), always taking
into account the patient’s total cardiovascular risk
profile.1,2,4
Clinical indications for HBPM
Given the fallibility of conventional office BP measure-
ments, HBPM provides clinically useful information
on BP level and profile to practising doctors, because
it enables a more precise initial diagnosis of hyper-
tension and more accurate titration of antihypertensive
drug treatment (Box 7). It also offers useful infor-
mation on home heart rate24 and on day-by-day BP
variability.9,10 Therefore, if feasible, it should be used
in all treated hypertensive patients. Its use is also
recommended for the identification of patients with
suspected white-coat or masked hypertension, (parti-
cularly among subjects with borderline or highly
variable office BP, high cardiovascular risk and normal
office BP, hypotension symptoms in spite of inade-
quate office BP control by treatment, no signs of organ
damage in spite of the high office BP).23,25,26 HBPM is
further recommended in patients with poor compli-
ance with treatment (HBPM may increase their
involvement in hypertension management), and pos-
sibly also in some high-risk populations in whom close
BP control is mandatory (pregnant women, renal and
diabetic patients). In pregnancy, HBPM should be
performedwith devices validated in this condition and
available evidence suggests that the diagnostic thresh-
olds should be the same as in the general population,
although more studies are needed on this issue.
A contraindication for HBPM performed with
oscillometric devices is the presence of relevant
arrhythmias (atrial fibrillation, numerous extrasys-
toles and important bradycardia) in which these
devices can be unreliable. However, recent evidence
suggests that in subjects with atrial fibrillation some
oscillometric devices may not be always inaccu-
rate—an issue that deserves further investigation.27
In these circumstances, HBPM may be performed
using auscultatory devices provided that the patient
has been properly trained, an approach, however,
which would require further investigation.
Conclusion
HBPM is a valuable tool in the daily management of
hypertension. However, it should be always used
under medical supervision and taking into account
the patients’ overall clinical conditions and cardio-
vascular risk profile.5,6
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